Racist history of research could hinder COVID-19 vaccines, but an Alabama university wants to help

Tuskegee University, which is linked to one of the most notorious medical experiments in U.S. history, wants to build trust between researchers and Black volunteers necessary for trials of COVID-19 vaccines.

Efforts to recruit Black volunteers for COVID-19 vaccine trials have stumbled this fall, despite high rates of hospitalizations and death in the African American community. Experts from Tuskegee University hope to change that by encouraging drug companies and researchers to adopt practices to protect vulnerable study participants.

Recently, four experts from Tuskegee and Harvard Universities wrote an article in the New England Journal of Medicine urging researchers to convince Black volunteers they can be trusted.

Black people account for 21 percent of the deaths from coronavirus but only 3 percent of vaccine volunteers. David Hodge, associate director of education at Tuskegee University’s National Center for Bioethics in Health Care and Research, said the lack of minority participation undermines trial

Read More

TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines

Company’s Thin Film Freezing dry powder was equivalent to the liquid universal influenza formulated vaccine in preclinical immunogenicity and efficacy testing

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that in collaboration with the University of Georgia’s (UGA) Center for Vaccines and Immunology (CVI) obtained positive preclinical immunogenicity and efficacy data from TFF formulated UGA universal Influenza hemagglutinin (HA) recombinant vaccines.

In April of 2020, TFFP and the University of Georgia’s CVI entered into a Research and Development Agreement to test the immunogenicity and efficacy of universal influenza HA recombinant vaccines following the TFF process. Animals were vaccinated with HA vaccines with or without adjuvants and challenged with H1N1 and H3N2 influenza viruses. The TFF HA vaccines elicited equivalent neutralizing antibodies and protection against influenza virus infection compared to

Read More

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals.

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — announces the release of the report “Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029” –
Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection.

Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended in the US, UK, Italy, and Spain for adolescents, and in Argentina for infants. In China, immunization

Read More

Charlie Baker applauds area’s key role in creating coronavirus vaccines

As public schools delve deeper into science, technology, engineering and math skill sets during this year’s STEM week, Gov. Charlie Baker said the pandemic has underscored the importance of the skills.

Charlie Baker wearing a suit and tie: BOSTON MA. OCTOBER 14: Gov. Charlie Baker speaks during a press conference at the State House announcing the budget for fiscal year 20201on October 14, 2020 in Boston, MA. (Staff Photo By Nancy Lane/MediaNews Group/Boston Herald)

© Provided by Boston Herald
BOSTON MA. OCTOBER 14: Gov. Charlie Baker speaks during a press conference at the State House announcing the budget for fiscal year 20201on October 14, 2020 in Boston, MA. (Staff Photo By Nancy Lane/MediaNews Group/Boston Herald)

“The fact that you currently have three companies — one of which was started here and two of which have big footprints here — that are currently in phase three clinical trials associated with COVID-19 just speaks to some extent to the power and the importance of having a community here in Massachusetts that is so dedicated to the STEM issues and has been for a really long time,” Baker said Monday, referring to Moderna, Pfizer and Johnson

Read More